Knee warmth is a common clinical observation following total knee arthroplasty (TKA). This can cause concern that infection is present. The purpose of our study was to establish the pattern of knee skin temperature following uncomplicated TKA. It was a prospective study carried out between 2001 and 2004. A pocket digital surface thermometer was used. A preliminary study established that the best site to measure knee skin temperature was superomedial to the patella and the best time was 12 noon. Patients with an increased risk of infection and those with a contralateral knee pathology or a previous surgery were excluded. Forty-eight patients fulfilled the inclusion criteria and consented to participate; the skin temperature of operated and contralateral knees was measured pre-operatively and daily during the first six weeks post-operatively. Measurements were also taken at 3, 6, 12 and 24 months following surgery. During the course of the study, patients developing complications of the operated knee or any pathology of the contralateral knee were excluded. Thirty-two patients completed the main study. Following surgery, systemic and both knees temperatures increased. Whereas systemic and contralateral knee temperatures settled within one week, the operated knee temperature took a longer time. The difference in temperature between the two knees had a mean value of +2.9°C at 7 days. This mean value decreased to +1.6°C at 6 weeks, +1.3°C at 3 months, +0.9°C at 6 months +0.3°C at 12 months and +0.04°C at 24 months. Following uncomplicated TKA, the operated knee skin temperature increases compared to the contralateral knee. This increase peaks at day 3 and diminishes slowly over several months; however, it remains statistically significant up to 6 months. These results correlate with the findings of previous studies that showed a prolonged elevation of inflammatory markers.
There is a difference of opinion regarding the usefulness of MR Imaging as a diagnostic tool for triangular fibrocartilage complex (TFCC) tears in the wrist. Our aim was to determine the accuracy of direct magnetic resonance arthrography (MRA) in the diagnosis of triangular fibrocartilage complex (TFCC) tears of the wrist in a district general hospital setting. In a retrospective review of 21 patients who presented with complains of wrist pain and following a clinical examination, all had direct MR arthrography of the wrist in our hospital in a 1.5Tesla scanner. All had a diagnostic arthroscopy within 2-4 months of the MR scan. All patients had chronic ulnar sided wrist pain, although only two had a definite history of trauma. The findings of each diagnostic method were compared, with arthroscopy considered the gold standard. Twenty-one patients were studied (10 male: 11 female), mean age 42 years (range 27-71) years). Seventeen TFCC tears were diagnosed on arthroscopy. For the diagnosis of TFCC tears MRA had a sensitivity, specificity and accuracy of 67%. Our results echoed the opinion of some of the previous investigators with an unacceptable sensitivity or specificity for a diagnostic tool. MR arthrography needs to be further refined as a technique before it can be considered to be accurate enough to replace wrist arthroscopy for the diagnosis of TFCC tears. Other centres have reported better accuracy, using more advanced MRI technology. Until this iswidely available at all levels of healthcare the results of MRI for the diagnosis of TFCC tears should be interpreted with caution.
Fifty-six patients with stage II-B osteosarcoma around the knee were followed-up for a minimum of 92 months. The percentage of tumour cells expressing VEGF/MMP-9 was assessed using immunohistochemistry. The relationship between VEGF/MMP-9 expression and survival was assessed using Kaplan-Meier and Cox regression models. Patients with tumours expressing VEGF in >25% of their cells had shorter overall (p=0.019) and disease-free survival (p=0.009). Patients with tumours expressing MMP-9 had shorter overall (p=0.0042) and disease-free survival (p=0.0004). There was an association between VEGF and MMP-9 expression (p=0.021). The negative effects of VEGF/MMP-9 expression on survival were independent of traditional prognostic factors.
Digital x-ray systems are now widely used in hospitals in the UK. Most systems have facilities to take measurements from the images that, we are lead to believe, can be used in accurate pre-operative planning. The aim of this study was to assess whether or not pre-operative planning can reliably predict the size of the implant required when using a hemiarthroplasty to treat an intracapsular hip fracture. A magnification factor was calculated for pre-operative pelvic x-rays using typical beam to plate distance and plate to hip distance. The pre-operative digital radiographs of 188 consecutive patients who underwent a hip hemiarthroplasty were examined. The femoral head diameters of both the fractured and non-fractured sides were measured. The size of the implanted prosthesis was also recorded from the patients’ operation notes. The x-ray measurements were multiplied by the magnification factor and compared with the known size of the prosthesis. The calculated magnification factor was 128%. Attempts at estimating implant size from measurements of the fractured and non-fractured sides underestimated the size of the prosthesis by 3.0mm (CI 6.5 to −0.5) and 3.1mm (CI 6.8 to −0.6) respectively. Many hospitals do not stock the full range of hemiarthroplasty implants on the shelf. Sizes at the extremes of the range may need to be specially ordered. It is important that the correct size prosthesis be inserted; an oversized prosthesis can increase the risk of dislocation and an undersized prosthesis will result in point loading and acetabular erosion. Our study shows that pre-operative planning consistently underestimates the size of the implant. However, the accuracy of these estimations is not sufficiently reliable, being +/− 3.5mm, to be able to accurately predict the size of the prosthesis required. Reasons for the under estimation are likely to be due to the fact that the measurement taken from the images does not account for the articular cartilage covering the femoral head. One of the factors leading to inaccuracy in the estimation is variation in patient anatomy and habitus, which affects hip to plate distance and thus the magnification factor. Also, the distance of the beam to plate will vary according to the radiographer’s positioning of the x-ray source. In order to accurately pre-operatively plan the size of the prosthesis one would need to standardise the beam to hip distance. radio-opaque markers would need to be positioned at the level of the hip in order to accurately calculate the magnification factor. Without these modifications, we do not feel that hip prosthesis size can be accurately predicted from pre-operative images.
Our study sets out to show whether vascular endothelial growth factor (VEGF) expression in stage 2B osteosarcomas around the knee influences disease-free and overall survival. Fifty-two such patients treated in out unit were identified and followed-up for for a minimum of 92 months. All were treated according to the current MRC protocol and had resection of their tumour. Tissue from their resected tumours was stained for VEGF using immunohistochemical methods and the percentage of tumour cells staining for VEGF was assessed. The relationship between VEGF expression and survival was assessed using the log-rank test and Kaplan-Meier survival curves. At follow-up 32 (62%) patients were dead, all from metastatic disease. Twenty-six (50%) tumours showed expression of VEGF. Statistical analysis showed that patients with tumours with VEGF expression in more than 25% of the cells had significantly shorter overall survival (p=0.019) and disease free intervals (p=0.009). Expression of VEGF also correlated with expression of the proteolytic enzyme MMP9 (p=0.02). VEGF is peptide which acts as a stimulator of new blood vessel growth in normal tissues, as well as in some solid tumours and their metastases. A tumour which is able to induce a blood supply has an increased ability to grow, seed metastases and threaten life. Our study is the first to look at VEGF expression in the tumour cells surviving after chemotherapy. It is this population of cells which is important as it is these cells which may go on to develop into metastatic or locally recurrent tumours. The over-expression of VEGF by osteosarcoma cells is thought to be associated with a worse prognosis due to a number of mechanisms. This study shows that VEGF expression is an important prognostic factor in osteosarcomas and suggests that the mechanisms by which VEGF and MMP9 expression produce a poor prognosis may be linked. Suppression of tumour angiogenesis by inhibition of the action of VEGF has shown promise in animal models as a potential new treatment for osteosarcoma, and warrants further study.